APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Adrenocortical Carcinoma Drugs

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Adrenocortical Carcinoma Drugs Market Analysis and Forecast 2026-2032

Report ID 173960780222 December 2025197 pages

Choose your research edition.

Industry ResearchAdrenocortical Carcinoma Drugs Industry Research Report 2026118 pages · $2,950 USDIndustry Growth & TrendsGlobal Adrenocortical Carcinoma Drugs Industry Growth and Trends Forecast to 203285 pages · $3,450 USDMarket StructureGlobal Adrenocortical Carcinoma Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032186 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Adrenocortical Carcinoma Drugs Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal Adrenocortical Carcinoma Drugs Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

The global Adrenocortical Carcinoma Drugs market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Adrenocortical Carcinoma Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Adrenocortical Carcinoma Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Adrenocortical Carcinoma Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Adrenocortical Carcinoma Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Adrenocortical Carcinoma Drugs include Teva Pharmaceutical Industries Ltd., Eli Lilly and Co., Bristol-Myers Squibb Co., Progenics Pharmaceuticals Inc. and Laboratoire HRA Pharma SAS, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Adrenocortical Carcinoma Drugs, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Adrenocortical Carcinoma Drugs, also provides the revenue of main regions and countries. Of the upcoming market potential for Adrenocortical Carcinoma Drugs, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Adrenocortical Carcinoma Drugs revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Adrenocortical Carcinoma Drugs market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Adrenocortical Carcinoma Drugs revenue, projected growth trends, production technology, application and end-user industry.

Adrenocortical Carcinoma Drugs Segment by Company

Teva Pharmaceutical Industries Ltd.

Eli Lilly and Co.

Bristol-Myers Squibb Co.

Progenics Pharmaceuticals Inc.

Laboratoire HRA Pharma SAS

Adrenocortical Carcinoma Drugs Segment by Type

Chemotherapy

Targeted therapy

Adrenocortical Carcinoma Drugs Segment by Application

Research institute

Hospital

Clinic

Other

Adrenocortical Carcinoma Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Adrenocortical Carcinoma Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Adrenocortical Carcinoma Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Adrenocortical Carcinoma Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Adrenocortical Carcinoma Drugs in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Adrenocortical Carcinoma Drugs company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Adrenocortical Carcinoma Drugs revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Adrenocortical Carcinoma Drugs Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Chemotherapy Major Player Table 3. Targeted therapy Major Player Table 4. Global Adrenocortical Carcinoma Drugs Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 5. Research institute Major Player Table 6. Hospital Major Player Table 7. Clinic Major Player Table 8. Other Major Player Table 9. Adrenocortical Carcinoma Drugs Industry Trends Table 10. Adrenocortical Carcinoma Drugs Industry Drivers Table 11. Adrenocortical Carcinoma Drugs Industry Opportunities and Challenges Table 12. Adrenocortical Carcinoma Drugs Industry Restraints Table 13. Global Adrenocortical Carcinoma Drugs Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 14. Global Adrenocortical Carcinoma Drugs Market Size by Region (2021-2026) & (US$ Million) Table 15. Global Adrenocortical Carcinoma Drugs Market Share by Region (2021-2026) Table 16. Global Adrenocortical Carcinoma Drugs Market Size by Region (2027-2032) & (US$ Million) Table 17. Global Adrenocortical Carcinoma Drugs Market Share by Region (2027-2032) Table 18. Global Adrenocortical Carcinoma Drugs Revenue by Players (US$ Million) & (2021-2026) Table 19. Global Adrenocortical Carcinoma Drugs Revenue Market Share by Players (2021-2026) Table 20. Global Adrenocortical Carcinoma Drugs Key Players Ranking, 2024 VS 2025 VS 2026 Table 21. Global Adrenocortical Carcinoma Drugs Key Players Headquarters & Area Served Table 22. Global Adrenocortical Carcinoma Drugs Players, Product Type & Application Table 23. Global Adrenocortical Carcinoma Drugs Players Establishment Date Table 24. Global Players Market Concentration Ratio (CR5 and HHI) Table 25. Global Adrenocortical Carcinoma Drugs by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 26. Global Adrenocortical Carcinoma Drugs Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Adrenocortical Carcinoma Drugs Revenue by Type (2021-2026) & (US$ Million) Table 28. Global Adrenocortical Carcinoma Drugs Revenue by Type (2027-2032) & (US$ Million) Table 29. Global Adrenocortical Carcinoma Drugs Revenue Market Share by Type (2021-2026) Table 30. Global Adrenocortical Carcinoma Drugs Revenue Market Share by Type (2027-2032) Table 31. Global Adrenocortical Carcinoma Drugs Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global Adrenocortical Carcinoma Drugs Revenue by Application (2021-2026) & (US$ Million) Table 33. Global Adrenocortical Carcinoma Drugs Revenue by Application (2027-2032) & (US$ Million) Table 34. Global Adrenocortical Carcinoma Drugs Revenue Market Share by Application (2021-2026) Table 35. Global Adrenocortical Carcinoma Drugs Revenue Market Share by Application (2027-2032) Table 36. Teva Pharmaceutical Industries Ltd. Company Information Table 37. Teva Pharmaceutical Industries Ltd. Business Overview Table 38. Teva Pharmaceutical Industries Ltd. Adrenocortical Carcinoma Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 39. Teva Pharmaceutical Industries Ltd. Adrenocortical Carcinoma Drugs Product Portfolio Table 40. Teva Pharmaceutical Industries Ltd. Recent Development Table 41. Eli Lilly and Co. Company Information Table 42. Eli Lilly and Co. Business Overview Table 43. Eli Lilly and Co. Adrenocortical Carcinoma Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 44. Eli Lilly and Co. Adrenocortical Carcinoma Drugs Product Portfolio Table 45. Eli Lilly and Co. Recent Development Table 46. Bristol-Myers Squibb Co. Company Information Table 47. Bristol-Myers Squibb Co. Business Overview Table 48. Bristol-Myers Squibb Co. Adrenocortical Carcinoma Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 49. Bristol-Myers Squibb Co. Adrenocortical Carcinoma Drugs Product Portfolio Table 50. Bristol-Myers Squibb Co. Recent Development Table 51. Progenics Pharmaceuticals Inc. Company Information Table 52. Progenics Pharmaceuticals Inc. Business Overview Table 53. Progenics Pharmaceuticals Inc. Adrenocortical Carcinoma Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 54. Progenics Pharmaceuticals Inc. Adrenocortical Carcinoma Drugs Product Portfolio Table 55. Progenics Pharmaceuticals Inc. Recent Development Table 56. Laboratoire HRA Pharma SAS Company Information Table 57. Laboratoire HRA Pharma SAS Business Overview Table 58. Laboratoire HRA Pharma SAS Adrenocortical Carcinoma Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 59. Laboratoire HRA Pharma SAS Adrenocortical Carcinoma Drugs Product Portfolio Table 60. Laboratoire HRA Pharma SAS Recent Development Table 61. North America Adrenocortical Carcinoma Drugs Revenue by Type (2021-2026) & (US$ Million) Table 62. North America Adrenocortical Carcinoma Drugs Revenue by Type (2027-2032) & (US$ Million) Table 63. North America Adrenocortical Carcinoma Drugs Revenue by Application (2021-2026) & (US$ Million) Table 64. North America Adrenocortical Carcinoma Drugs Revenue by Application (2027-2032) & (US$ Million) Table 65. North America Adrenocortical Carcinoma Drugs Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 66. North America Adrenocortical Carcinoma Drugs Revenue by Country (2021-2026) & (US$ Million) Table 67. North America Adrenocortical Carcinoma Drugs Revenue by Country (US$ Million) & (2027-2032) Table 68. Europe Adrenocortical Carcinoma Drugs Revenue by Type (2021-2026) & (US$ Million) Table 69. Europe Adrenocortical Carcinoma Drugs Revenue by Type (2027-2032) & (US$ Million) Table 70. Europe Adrenocortical Carcinoma Drugs Revenue by Application (2021-2026) & (US$ Million) Table 71. Europe Adrenocortical Carcinoma Drugs Revenue by Application (2027-2032) & (US$ Million) Table 72. Europe Adrenocortical Carcinoma Drugs Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 73. Europe Adrenocortical Carcinoma Drugs Revenue by Country (2021-2026) & (US$ Million) Table 74. Europe Adrenocortical Carcinoma Drugs Revenue by Country (US$ Million) & (2027-2032) Table 75. China Adrenocortical Carcinoma Drugs Revenue by Type (2021-2026) & (US$ Million) Table 76. China Adrenocortical Carcinoma Drugs Revenue by Type (2027-2032) & (US$ Million) Table 77. China Adrenocortical Carcinoma Drugs Revenue by Application (2021-2026) & (US$ Million) Table 78. China Adrenocortical Carcinoma Drugs Revenue by Application (2027-2032) & (US$ Million) Table 79. Asia Adrenocortical Carcinoma Drugs Revenue by Type (2021-2026) & (US$ Million) Table 80. Asia Adrenocortical Carcinoma Drugs Revenue by Type (2027-2032) & (US$ Million) Table 81. Asia Adrenocortical Carcinoma Drugs Revenue by Application (2021-2026) & (US$ Million) Table 82. Asia Adrenocortical Carcinoma Drugs Revenue by Application (2027-2032) & (US$ Million) Table 83. Asia Adrenocortical Carcinoma Drugs Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 84. Asia Adrenocortical Carcinoma Drugs Revenue by Region (US$ Million) & (2021-2026) Table 85. Asia Adrenocortical Carcinoma Drugs Revenue by Region (US$ Million) & (2027-2032) Table 86. SAMEA Adrenocortical Carcinoma Drugs Revenue by Type (2021-2026) & (US$ Million) Table 87. SAMEA Adrenocortical Carcinoma Drugs Revenue by Type (2027-2032) & (US$ Million) Table 88. SAMEA Adrenocortical Carcinoma Drugs Revenue by Application (2021-2026) & (US$ Million) Table 89. SAMEA Adrenocortical Carcinoma Drugs Revenue by Application (2027-2032) & (US$ Million) Table 90. SAMEA Adrenocortical Carcinoma Drugs Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 91. SAMEA Adrenocortical Carcinoma Drugs Revenue by Country (2021-2026) & (US$ Million) Table 92. SAMEA Adrenocortical Carcinoma Drugs Revenue by Country (US$ Million) & (2027-2032) Table 93. Research Programs/Design for This Report Table 94. Authors List of This Report Table 95. Secondary Sources Table 96. Primary Sources List of Figures Figure 1. Adrenocortical Carcinoma Drugs Image Figure 2. Global Adrenocortical Carcinoma Drugs Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Adrenocortical Carcinoma Drugs Market Size Share 2021 VS 2025 VS 2032 Figure 4. Chemotherapy Image Figure 5. Targeted therapy Image Figure 6. Global Adrenocortical Carcinoma Drugs Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 7. Global Adrenocortical Carcinoma Drugs Market Size Share 2021 VS 2025 VS 2032 Figure 8. Research institute Image Figure 9. Hospital Image Figure 10. Clinic Image Figure 11. Other Image Figure 12. Global Adrenocortical Carcinoma Drugs Market Size (US$ Million) & (2021-2032) Figure 13. Global Adrenocortical Carcinoma Drugs Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 14. Global Adrenocortical Carcinoma Drugs Market Share by Region: 2021 VS 2025 VS 2032 Figure 15. Global Adrenocortical Carcinoma Drugs Players Revenue Share Top 10 and Top 5 in 2025 Figure 16. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 17. Global Adrenocortical Carcinoma Drugs Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Adrenocortical Carcinoma Drugs Revenue Market Share 2021 VS 2025 VS 2032 Figure 19. Global Adrenocortical Carcinoma Drugs Revenue Market Share by Type (2021-2032) Figure 20. Global Adrenocortical Carcinoma Drugs Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 21. Global Adrenocortical Carcinoma Drugs Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 22. Global Adrenocortical Carcinoma Drugs Revenue Market Share by Application (2021-2032) Figure 23. North America Adrenocortical Carcinoma Drugs Revenue YoY Growth (2021-2032) & (US$ Million) Figure 24. North America Adrenocortical Carcinoma Drugs Revenue Share by Type (2021-2032) Figure 25. North America Adrenocortical Carcinoma Drugs Revenue Share by Application (2021-2032) Figure 26. North America Adrenocortical Carcinoma Drugs Revenue Share by Country (2021-2032) Figure 27. United States Adrenocortical Carcinoma Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 28. Canada Adrenocortical Carcinoma Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Mexico Adrenocortical Carcinoma Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Europe Adrenocortical Carcinoma Drugs Revenue YoY Growth (2021-2032) & (US$ Million) Figure 31. Europe Adrenocortical Carcinoma Drugs Revenue Share by Type (2021-2032) Figure 32. Europe Adrenocortical Carcinoma Drugs Revenue Share by Application (2021-2032) Figure 33. Europe Adrenocortical Carcinoma Drugs Revenue Share by Country (2021-2032) Figure 34. Germany Adrenocortical Carcinoma Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 35. France Adrenocortical Carcinoma Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. U.K. Adrenocortical Carcinoma Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. Italy Adrenocortical Carcinoma Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Spain Adrenocortical Carcinoma Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Russia Adrenocortical Carcinoma Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Netherlands Adrenocortical Carcinoma Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Nordic Countries Adrenocortical Carcinoma Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. China Adrenocortical Carcinoma Drugs Revenue YoY Growth (2021-2032) & (US$ Million) Figure 43. China Adrenocortical Carcinoma Drugs Revenue Share by Type (2021-2032) Figure 44. China Adrenocortical Carcinoma Drugs Revenue Share by Application (2021-2032) Figure 45. Asia Adrenocortical Carcinoma Drugs Revenue YoY Growth (2021-2032) & (US$ Million) Figure 46. Asia Adrenocortical Carcinoma Drugs Revenue Share by Type (2021-2032) Figure 47. Asia Adrenocortical Carcinoma Drugs Revenue Share by Application (2021-2032) Figure 48. Asia Adrenocortical Carcinoma Drugs Revenue Share by Region (2021-2032) Figure 49. Japan Adrenocortical Carcinoma Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 50. South Korea Adrenocortical Carcinoma Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. India Adrenocortical Carcinoma Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. Australia Adrenocortical Carcinoma Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Taiwan Adrenocortical Carcinoma Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Southeast Asia Adrenocortical Carcinoma Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. SAMEA Adrenocortical Carcinoma Drugs Revenue YoY Growth (2021-2032) & (US$ Million) Figure 56. SAMEA Adrenocortical Carcinoma Drugs Revenue Share by Type (2021-2032) Figure 57. SAMEA Adrenocortical Carcinoma Drugs Revenue Share by Application (2021-2032) Figure 58. SAMEA Adrenocortical Carcinoma Drugs Revenue Share by Country (2021-2032) Figure 59. Brazil Adrenocortical Carcinoma Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 60. Argentina Adrenocortical Carcinoma Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Chile Adrenocortical Carcinoma Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Colombia Adrenocortical Carcinoma Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Peru Adrenocortical Carcinoma Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Saudi Arabia Adrenocortical Carcinoma Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Israel Adrenocortical Carcinoma Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. UAE Adrenocortical Carcinoma Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Turkey Adrenocortical Carcinoma Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Iran Adrenocortical Carcinoma Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Egypt Adrenocortical Carcinoma Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Years Considered Figure 71. Research Process Figure 72. Key Executives Interviewed

Scope & coverage.

Types
  • Chemotherapy
  • Targeted therapy
Applications
  • Research institute
  • Hospital
  • Clinic
  • Other
Companies covered
  • Teva Pharmaceutical Industries Ltd.
  • Eli Lilly and Co.
  • Bristol-Myers Squibb Co.
  • Progenics Pharmaceuticals Inc.
  • Laboratoire HRA Pharma SAS

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Adrenocortical Carcinoma Drugs Market by Type
  3. 1.2.1 Global Adrenocortical Carcinoma Drugs Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Chemotherapy
  5. 1.2.3 Targeted therapy
  6. 1.3 Adrenocortical Carcinoma Drugs Market by Application
  7. 1.3.1 Global Adrenocortical Carcinoma Drugs Market Size by Application, 2021 VS 2025 VS 2032
  8. 1.3.2 Research institute
  9. 1.3.3 Hospital
  10. 1.3.4 Clinic
  11. 1.3.5 Other
  12. 1.4 Assumptions and Limitations
  13. 1.5 Study Goals and Objectives
2 Adrenocortical Carcinoma Drugs Market Dynamics
  1. 2.1 Adrenocortical Carcinoma Drugs Industry Trends
  2. 2.2 Adrenocortical Carcinoma Drugs Industry Drivers
  3. 2.3 Adrenocortical Carcinoma Drugs Industry Opportunities and Challenges
  4. 2.4 Adrenocortical Carcinoma Drugs Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Adrenocortical Carcinoma Drugs Market Perspective (2021-2032)
  2. 3.2 Global Adrenocortical Carcinoma Drugs Growth Trends by Region
  3. 3.2.1 Global Adrenocortical Carcinoma Drugs Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Adrenocortical Carcinoma Drugs Market Size by Region (2021-2026)
  5. 3.2.3 Global Adrenocortical Carcinoma Drugs Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Adrenocortical Carcinoma Drugs Revenue by Players
  2. 4.1.1 Global Adrenocortical Carcinoma Drugs Revenue by Players (2021-2026)
  3. 4.1.2 Global Adrenocortical Carcinoma Drugs Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Adrenocortical Carcinoma Drugs Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Adrenocortical Carcinoma Drugs Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Adrenocortical Carcinoma Drugs Key Players Headquarters & Area Served
  7. 4.4 Global Adrenocortical Carcinoma Drugs Players, Product Type & Application
  8. 4.5 Global Adrenocortical Carcinoma Drugs Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Adrenocortical Carcinoma Drugs Market CR5 and HHI
  11. 4.6.3 2025 Adrenocortical Carcinoma Drugs Tier 1, Tier 2, and Tier 3
5 Adrenocortical Carcinoma Drugs Market Size by Type
  1. 5.1 Global Adrenocortical Carcinoma Drugs Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Adrenocortical Carcinoma Drugs Revenue by Type (2021-2032)
  3. 5.3 Global Adrenocortical Carcinoma Drugs Revenue Market Share by Type (2021-2032)
6 Adrenocortical Carcinoma Drugs Market Size by Application
  1. 6.1 Global Adrenocortical Carcinoma Drugs Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Adrenocortical Carcinoma Drugs Revenue by Application (2021-2032)
  3. 6.3 Global Adrenocortical Carcinoma Drugs Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Teva Pharmaceutical Industries Ltd.
  2. 7.1.1 Teva Pharmaceutical Industries Ltd. Company Information
  3. 7.1.2 Teva Pharmaceutical Industries Ltd. Business Overview
  4. 7.1.3 Teva Pharmaceutical Industries Ltd. Adrenocortical Carcinoma Drugs Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Teva Pharmaceutical Industries Ltd. Adrenocortical Carcinoma Drugs Product Portfolio
  6. 7.1.5 Teva Pharmaceutical Industries Ltd. Recent Developments
  7. 7.2 Eli Lilly and Co.
  8. 7.2.1 Eli Lilly and Co. Company Information
  9. 7.2.2 Eli Lilly and Co. Business Overview
  10. 7.2.3 Eli Lilly and Co. Adrenocortical Carcinoma Drugs Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Eli Lilly and Co. Adrenocortical Carcinoma Drugs Product Portfolio
  12. 7.2.5 Eli Lilly and Co. Recent Developments
  13. 7.3 Bristol-Myers Squibb Co.
  14. 7.3.1 Bristol-Myers Squibb Co. Company Information
  15. 7.3.2 Bristol-Myers Squibb Co. Business Overview
  16. 7.3.3 Bristol-Myers Squibb Co. Adrenocortical Carcinoma Drugs Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Bristol-Myers Squibb Co. Adrenocortical Carcinoma Drugs Product Portfolio
  18. 7.3.5 Bristol-Myers Squibb Co. Recent Developments
  19. 7.4 Progenics Pharmaceuticals Inc.
  20. 7.4.1 Progenics Pharmaceuticals Inc. Company Information
  21. 7.4.2 Progenics Pharmaceuticals Inc. Business Overview
  22. 7.4.3 Progenics Pharmaceuticals Inc. Adrenocortical Carcinoma Drugs Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Progenics Pharmaceuticals Inc. Adrenocortical Carcinoma Drugs Product Portfolio
  24. 7.4.5 Progenics Pharmaceuticals Inc. Recent Developments
  25. 7.5 Laboratoire HRA Pharma SAS
  26. 7.5.1 Laboratoire HRA Pharma SAS Company Information
  27. 7.5.2 Laboratoire HRA Pharma SAS Business Overview
  28. 7.5.3 Laboratoire HRA Pharma SAS Adrenocortical Carcinoma Drugs Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Laboratoire HRA Pharma SAS Adrenocortical Carcinoma Drugs Product Portfolio
  30. 7.5.5 Laboratoire HRA Pharma SAS Recent Developments
8 North America
  1. 8.1 North America Adrenocortical Carcinoma Drugs Revenue (2021-2032)
  2. 8.2 North America Adrenocortical Carcinoma Drugs Revenue by Type (2021-2032)
  3. 8.2.1 North America Adrenocortical Carcinoma Drugs Revenue by Type (2021-2026)
  4. 8.2.2 North America Adrenocortical Carcinoma Drugs Revenue by Type (2027-2032)
  5. 8.3 North America Adrenocortical Carcinoma Drugs Revenue Share by Type (2021-2032)
  6. 8.4 North America Adrenocortical Carcinoma Drugs Revenue by Application (2021-2032)
  7. 8.4.1 North America Adrenocortical Carcinoma Drugs Revenue by Application (2021-2026)
  8. 8.4.2 North America Adrenocortical Carcinoma Drugs Revenue by Application (2027-2032)
  9. 8.5 North America Adrenocortical Carcinoma Drugs Revenue Share by Application (2021-2032)
  10. 8.6 North America Adrenocortical Carcinoma Drugs Revenue by Country
  11. 8.6.1 North America Adrenocortical Carcinoma Drugs Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Adrenocortical Carcinoma Drugs Revenue by Country (2021-2026)
  13. 8.6.3 North America Adrenocortical Carcinoma Drugs Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Adrenocortical Carcinoma Drugs Revenue (2021-2032)
  2. 9.2 Europe Adrenocortical Carcinoma Drugs Revenue by Type (2021-2032)
  3. 9.2.1 Europe Adrenocortical Carcinoma Drugs Revenue by Type (2021-2026)
  4. 9.2.2 Europe Adrenocortical Carcinoma Drugs Revenue by Type (2027-2032)
  5. 9.3 Europe Adrenocortical Carcinoma Drugs Revenue Share by Type (2021-2032)
  6. 9.4 Europe Adrenocortical Carcinoma Drugs Revenue by Application (2021-2032)
  7. 9.4.1 Europe Adrenocortical Carcinoma Drugs Revenue by Application (2021-2026)
  8. 9.4.2 Europe Adrenocortical Carcinoma Drugs Revenue by Application (2027-2032)
  9. 9.5 Europe Adrenocortical Carcinoma Drugs Revenue Share by Application (2021-2032)
  10. 9.6 Europe Adrenocortical Carcinoma Drugs Revenue by Country
  11. 9.6.1 Europe Adrenocortical Carcinoma Drugs Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Adrenocortical Carcinoma Drugs Revenue by Country (2021-2026)
  13. 9.6.3 Europe Adrenocortical Carcinoma Drugs Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Adrenocortical Carcinoma Drugs Revenue (2021-2032)
  2. 10.2 China Adrenocortical Carcinoma Drugs Revenue by Type (2021-2032)
  3. 10.2.1 China Adrenocortical Carcinoma Drugs Revenue by Type (2021-2026)
  4. 10.2.2 China Adrenocortical Carcinoma Drugs Revenue by Type (2027-2032)
  5. 10.3 China Adrenocortical Carcinoma Drugs Revenue Share by Type (2021-2032)
  6. 10.4 China Adrenocortical Carcinoma Drugs Revenue by Application (2021-2032)
  7. 10.4.1 China Adrenocortical Carcinoma Drugs Revenue by Application (2021-2026)
  8. 10.4.2 China Adrenocortical Carcinoma Drugs Revenue by Application (2027-2032)
  9. 10.5 China Adrenocortical Carcinoma Drugs Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Adrenocortical Carcinoma Drugs Revenue (2021-2032)
  2. 11.2 Asia Adrenocortical Carcinoma Drugs Revenue by Type (2021-2032)
  3. 11.2.1 Asia Adrenocortical Carcinoma Drugs Revenue by Type (2021-2026)
  4. 11.2.2 Asia Adrenocortical Carcinoma Drugs Revenue by Type (2027-2032)
  5. 11.3 Asia Adrenocortical Carcinoma Drugs Revenue Share by Type (2021-2032)
  6. 11.4 Asia Adrenocortical Carcinoma Drugs Revenue by Application (2021-2032)
  7. 11.4.1 Asia Adrenocortical Carcinoma Drugs Revenue by Application (2021-2026)
  8. 11.4.2 Asia Adrenocortical Carcinoma Drugs Revenue by Application (2027-2032)
  9. 11.5 Asia Adrenocortical Carcinoma Drugs Revenue Share by Application (2021-2032)
  10. 11.6 Asia Adrenocortical Carcinoma Drugs Revenue by Country
  11. 11.6.1 Asia Adrenocortical Carcinoma Drugs Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Adrenocortical Carcinoma Drugs Revenue by Country (2021-2026)
  13. 11.6.3 Asia Adrenocortical Carcinoma Drugs Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Adrenocortical Carcinoma Drugs Revenue (2021-2032)
  2. 12.2 SAMEA Adrenocortical Carcinoma Drugs Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Adrenocortical Carcinoma Drugs Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Adrenocortical Carcinoma Drugs Revenue by Type (2027-2032)
  5. 12.3 SAMEA Adrenocortical Carcinoma Drugs Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Adrenocortical Carcinoma Drugs Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Adrenocortical Carcinoma Drugs Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Adrenocortical Carcinoma Drugs Revenue by Application (2027-2032)
  9. 12.5 SAMEA Adrenocortical Carcinoma Drugs Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Adrenocortical Carcinoma Drugs Revenue by Country
  11. 12.6.1 SAMEA Adrenocortical Carcinoma Drugs Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Adrenocortical Carcinoma Drugs Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Adrenocortical Carcinoma Drugs Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst